恶性黑色素瘤临床特征及治疗方式与预后的相关分析

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (2159 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的: 分析影响恶性黑色素瘤患者预后的相关因素。方法: 收集64例恶性黑色素瘤患者病史资料，记录治疗方案并随访2年。随访结束后，整理相关数据，使用SPSS 22.0统计软件分析，KaplanMeier法绘制生存曲线，Logrank检验比较2年生存率，分析筛选预后相关影响因素。结果：汇总病例数据，其中，男34例，女30例，平均发病年龄62岁；1年、2年生存率分别为80.6%、35.4%。统计分析显示，肿瘤发生部位、有无早期淋巴结转移及肿瘤破溃、手术方式等因素与2年生存率相关，而年龄、性别、疼痛感、术后放化疗及生物免疫治疗等因素对预后的影响尚不明确。结论：黏膜部位及初发部位不明确的肿瘤、确诊时肿瘤破溃、早期淋巴结转移提示恶性黑色素瘤预后差。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：恶性黑色素瘤, 复发, 转移, 生存时间, 预后

Abstract：Objective: To explore the prognostic factors of malignant melanoma patients. Methods: The clinical data and treatment protocol of 64 patients with malignant melanoma were collected. All patients were followed up for 2 years and then the data were analyzed. The survival rate was calculated by KaplanMeier method, the survival curve was drawn by Logrank method and the survival rate of each group was compared. Results: The mean age of onset was 62 years, the 1year and 2year survival rates were 80.6% and 35.4%, respectively. Tumor location, ulceration, lymph node metastasis, surgical types were significantly associated with 2year survival rate, but effects of age, sex, pain, postoperative radiotherapy, chemotherapy or biological immunotherapy on survival rates were not clear. Conclusion: Tumors occur in the mucosa or not identified, early lymph node metastasis and tumors ulceration were significantly associated with poor prognosis.

收稿日期: 2017-03-01

通讯作者: 李遇梅（通讯作者）.主任医师，E-mail: l.yumei@aliyun.com

作者简介: 王莹（1989—），女，硕士研究生

引用本文:

王莹，黄建玲，刘莉萍，许辉，李遇梅. 恶性黑色素瘤临床特征及治疗方式与预后的相关分析[J]. 江苏大学学报:医学版, 2017, 27(5): 428-431. WANG Ying, HUANG Jian-ling, LIU Li-ping, XU Hui, LI Yu-mei. Clinical characteristics and treatment of malignant melanoma and its prognosis analysis. Journal of Jiangsu University(Medicine Edition), 2017, 27(5): 428-431.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2017/V27/I5/428

[1\]Jemal A, Siegel R, Xu J, et al. Cancer statistics,2010\[J\]. CA Cancer J Clin, 2010, 60(5): 277-300.
\[2\]曾红梅, 张思维, 郑荣寿, 等. 2003～2007年中国皮肤黑色素瘤发病与死亡分析\[J\]. 中国肿瘤, 2012, 21(3): 183-189.
\[3\]CSCO黑色素瘤专家委员会. 中国黑色素瘤诊治指南(2011版)\[J\]. 临床肿瘤学杂志, 2012, 17(2): 159-171.
\[4\]Callender GG, Egger ME, Burton AL, et al. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker\[J\]. Am J Surg, 2011, 202(6): 659-664.
\[5\]BirchJohansen F, Hvilsom G, Kjaer T, et al. Social inequality and incidence of and survival from malignant melanoma in a populationbased study in Denmark, 1994-2003\[J\]. Eur J Cancer, 2008, 44(14): 2043-2049.
\[6\]Strmberg U, Holmén A, Peterson S. Spatial disparities in melanoma incidence and prognosis with consideration to stage at diagnosis, gender and marital status\[J\]. Spat Spatiotemporal Epidemiol, 2016, 19: 21-27.
\[7\]迟志宏, 盛锡楠, 李思明, 等. 357例中国皮肤黑色素瘤临床特征与预后分析\[J\]. 肿瘤防治研究, 2011, 38(11): 1316-1319.
\[8\]Xu X, Chen L, Guerry D, et al. Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma\[J\]. Clin Cancer Res, 2012, 18(1): 229-237.
\[9\]Eggermont AM, Spatz A, Lazar V, et al. Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?\[J\]. Curr Opin Oncol, 2012, 24(2): 137-140.
\[10\]Morton DL. Overview and update of the phase Ⅲ Multicenter Selective Lymphadenectomy Trials (MSLTⅠ and MSLTⅡ) in melanoma\[J\]. Clin Exp Metastasis, 2012, 29(7): 699-706.
\[11\]Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma\[J\]. Nat Rev Clin Oncol, 2013, 10(10): 588-598.
\[12\]庞得全, 郑维国, 胡雷，等. 恶性黑色素瘤预后影响因素的Cox分析\[J\]. 山东医药, 2011, 51(12)：89-91.
\[13\]李曙光, 黎莉. 93例转移性恶性黑色素瘤预后分析\[J\]. 中国肿瘤临床, 2004, 31(8): 446-448.
\[14\]王亚丽, 石光跃, 龚海燕, 等. 333例恶性黑色素瘤患者的预后相关因素分析\[J\]. 现代肿瘤医学, 2014, 22(2): 444-447.